Temperature-controlled supply chain firm Cryoport has sold its CRYOPDP business, a courier focused on clinical trials, biopharma, and cell and gene therapies, to German logistics multinational DHL Group.
In addition to the business sale, Cryoport has also confirmed a partnership with DHL to strengthen their respective offerings.
For DHL, the deal will enhance its capabilities in pharma logistics and expand its offering in the life sciences sector.
Oscar de Bok, CEO of DHL Supply Chain, described the purchase as a “pivotal move” for the company’, as it would allow the company to offer more to its pharma-specialised network.
… to continue reading this article and more, please login, register for free, or consider subscribing to gasworld
